Humacyte

Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason and Juliana L. Blum in October 13, 2004 and is headquartered in Durham, NC.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humacyte reports progress in trials and collaborations, poised for growth

Humacyte's Q4 2022 performance reflects a strong cash position, progress in key trials, and preparations for commercial activities. The company's strengths lie in innovative programs, strategic collaborations, and promising trial outcomes. Challenges include enrollment disruptions, regulatory complexities, and strategic planning considerations.
Opportunities for Humacyte include expanding its product portfolio, pursuing accelerated approvals, and leveraging successful trial outcomes for partnerships and market entry. With a focus on commercial readiness and visibility enhancement, Humacyte is poised for growth and advancement in the biotechnology sector.

Humacyte advances HAV trials, secures funding for commercial launch

Humacyte's Q1 2023 performance reflects promising advancements in vascular trauma treatments and strategic collaborations for product development.
While the company faces challenges in financing and regulatory processes, opportunities lie in market expansion and innovative partnerships.
Overall, Humacyte's progress in trials and financial stability position it well for future growth and potential market success.

Humacyte progresses HAV program, eyes growth through strategic collaborations

Humacyte's Q2 2023 earnings call highlighted advancements in the HAV program, positive outcomes in trauma indications, and strategic collaborations. While facing financial challenges with no revenue generated, the company's strong partnerships and funding support present opportunities for future growth and innovation.

Humacyte plans BLA submission for HAV after positive trial results

Humacyte's Q3 2023 performance reflected no revenue, a net loss of $26.0 million, and $100 million in cash and cash equivalents.
The Human Acellular Vessel (HAV) demonstrated superior outcomes in clinical trials and real-world applications, positioning it well for market adoption.
While financial challenges exist, the company's strategic focus on commercial launch preparation and real-world evidence collection presents growth opportunities.
Navigating market acceptance, reimbursement, and competition will be key for Humacyte's success in the biologics space.

Humacyte achieves FDA milestone with HAV, eyes market expansion

Humacyte made significant progress with FDA acceptance of BLA for HAV, showcasing superior outcomes and cost-saving potential.
Financially, the company had a strong cash position and aims for improved margins despite increased expenses in 2024.
Challenges include managing increased expenses and achieving superiority across patient groups, while opportunities lie in market expansion and operational efficiencies.
Overall, Humacyte's performance, strengths, challenges, and opportunities position it for growth and impact in the medical field.

Humacyte reports improved financials and advances FDA approval for HAV

Humacyte's Q1 2024 performance reflects a decrease in net loss, strong financial management, and progress in key clinical trials and product development.
The company's strengths lie in FDA milestones, strategic funding, research focus on high-impact areas, and financial stability.
Challenges include managing operating expenses, financial pressures, trial outcomes uncertainty, and successful market entry post-approval.
Opportunities abound in FDA approval prospects, market expansion, product diversification, and leveraging financial resources for growth initiatives.

Humacyte reports progress in key programs despite FDA delay

Humacyte's Q2 2024 earnings call highlighted progress in key programs, financial challenges due to FDA delay, and optimism for future growth. The company's strong financial position and strategic additions to the Board of Directors bode well for upcoming commercialization efforts.

Humacyte reports Q3 losses, highlights innovation and growth opportunities

Humacyte's Q3 2024 performance reflected significant investment in R&D and G&A expenses, resulting in a net loss of $39.2 million.
Positive trial outcomes and patent approvals underscore the company's innovation and potential for future revenue streams.
While facing financial challenges and regulatory uncertainties, Humacyte's strong cash position and ongoing trials offer opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period").

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues.

Robbins LLP Urges HUMA Stockholders with Large Losses to Contact the Firm for Information About the Humacyte, Inc. Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)---- $HUMA #CLASSACTIONLAWSUIT--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period”). Investors have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click h.

Kirby McInerney LLP Reminds Humacyte (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.

Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Impacted Investors Are Invited To Assist The Schall Law Firm

DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36th Annual Healthcare Conference, in New York, NY on Thursday, December 5, 2024. Management will also be available for one-on-one meetings.

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humacyte, Inc. - HUMA

LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.

Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Impacted Investors Should Assist The Schall Law Firm

NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA

HUMA Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / November 29, 2024 / Humacyte, Inc. (NASDAQ:HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v.

Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues - Hagens Berman

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=114142&wire=1 or contact Joseph E. Levi, Esq.

Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of January 17, 2025 - HUMA

LOS ANGELES, CA / ACCESSWIRE / November 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.

The Schall Law Firm Encourages Shareholders With Losses To Join A Fraud Case Against Humacyte Inc

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113883&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period”). Investors have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Kirby McInerney LLP Reminds Humacyte, Inc. (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113703&wire=1 or contact Joseph E. Levi, Esq.

Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).

The Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA

LOS ANGELES, CA / ACCESSWIRE / November 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.

The Schall Law Firm Urges Stockholders With Losses In Humacyte Inc To Join A Securities Fraud Case

NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period").

HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v.

Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman

LOS ANGELES, CA / ACCESSWIRE / November 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.

Humacyte, Inc. Is Being Sued For Violating Securities Laws And Affected Investors Can Assist The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113461&wire=1 or contact Joseph E. Levi, Esq.

Investors who Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky About Pending Class Action - HUMA

SAN DIEGO, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP  reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues.

Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action

LOS ANGELES, CA / ACCESSWIRE / November 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.

Humacyte, Inc. Is Being Sued For Violating Securities Regulations And Affected Investors Are Invited To Contact The Schall Law Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Investors suffering losses on their Humacyte investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal ri.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)

NEW YORK, NY / ACCESSWIRE / November 22, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=113165&wire=1 or contact Joseph E. Levi, Esq.

News for Humacyte Stock (HUMA)